Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Artara Therapeutics Inc (TARA)

Artara Therapeutics Inc (TARA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Artara Therapeutics Inc 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 USA

www.protaratx.com P: 646-844-0337

Description:

Protara Therapeutics Inc. is committed to identifying and advancing transformative therapies for rare and specialty diseases. The company's portfolio includes, TARA-002, an investigational cell therapy being developed for the treatment of lymphatic malformations, and intravenous Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. Protara Therapeutics Inc., formerly known as ArTara Therapeutics, is based in NEW YORK, United States.

Key Statistics

Overview:

Market Capitalization, $K 31,444
Enterprise Value, $K -8,147
Shares Outstanding, K 11,434
Annual Sales, $ 0 K
Annual Net Income, $ -40,420 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -10,220 K
EBIT, $ -43,610 K
EBITDA, $ -42,700 K
60-Month Beta 1.71
% of Insider Shareholders 18.40%
% of Institutional Shareholders 38.13%
Float, K 9,330
% Float 81.60%
Short Volume Ratio 0.59

Growth:

1-Year Return -13.73%
3-Year Return -77.44%
5-Year Return -83.63%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 92.24%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.90 on 03/13/24
Latest Earnings Date 05/02/24
Earnings Per Share ttm -3.57
EPS Growth vs. Prev Qtr -3.45%
EPS Growth vs. Prev Year -7.14%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-40 on 01/10/20

TARA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -49.71%
Return-on-Assets % -43.82%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.47
Book Value/Share 6.01
Interest Coverage -1.17
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar